Pembrolizumab (PEMBRO; MK-3475) for advanced melanoma (MEL): randomized comparison of two dosing schedules

C. Robert, A. M. Joshua, J. S. Weber, A. Ribas, F. S. Hodi, R. F. Kefford, A. Daud, J. D. Wolchok, W-J. Hwu, T. C. Gangadhar, A. Patnaik, P. Hersey, R. Dronca, H. Zarour, Y. Ge, J. A. Lindia, M. Giannotti, S. Ebbinghaus, S. P. Kang, O. Hamid

Research output: Contribution to journalMeeting abstractpeer-review

Fingerprint

Dive into the research topics of 'Pembrolizumab (PEMBRO; MK-3475) for advanced melanoma (MEL): randomized comparison of two dosing schedules'. Together they form a unique fingerprint.

Medicine & Life Sciences